Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Other Working Capital Changes (2021 - 2024)

Opus Genetics (IRD) has disclosed Other Working Capital Changes for 8 consecutive years, with $615000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Other Working Capital Changes fell 27.48% to $615000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$354000.0, a 354.68% decrease, with the full-year FY2024 number at -$634000.0, down 79.1% from a year prior.
  • Other Working Capital Changes was $615000.0 for Q4 2023 at Opus Genetics, up from -$248000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $848000.0 in Q4 2022 to a low of -$472000.0 in Q2 2021.
  • A 3-year average of -$84000.0 and a median of -$248000.0 in 2023 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 65.91% in 2022; the steepest drop was 237.74% in 2022.
  • Opus Genetics' Other Working Capital Changes stood at -$396000.0 in 2021, then surged by 314.14% to $848000.0 in 2022, then dropped by 27.48% to $615000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRD's Other Working Capital Changes are $615000.0 (Q4 2023), -$248000.0 (Q3 2023), and -$356000.0 (Q2 2023).